Menu
Gibson Lab
News & Impact

You are here

Home > Benfotiamine in Alzheimer's Disease: A Pilot Study (Benfotiamine)

Benfotiamine in Alzheimer's Disease: A Pilot Study (Benfotiamine)

September 1, 2014 to May 31, 2019
GRANT: 
Federal
Funding Status: 
Completed Project
Funding Agency: 
National Institutes of Health (NIH)
Funding Institute: 
National Institute on Aging (NIA)
Grant Number: 
R01AG043679
Published Grant: 
NIH RePORT

Goals

The proposed pilot clinical trial has the potential to identify a new, safe intervention aimed at modifying biological and clinical processes of AD progression that could inform a larger clinical trial.

Investigators

Gary E. Gibson, Ph.D.
Lab Director
Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration
Professor
Weill Cornell Medicine
Role: 
Principal Investigator
Photo of Pasquale
Pasquale Fonzetti, M.D., Ph.D.
COLLABORATOR
Chairman
Director and Staff Neurologist
Burke Rehabilitation Hospital
Assistant Professor of Neurology
Weill Cornell Medicine
Role: 
Principal Investigator

Associated

Research Labs: 
Gibson Lab

Conditions & Recovery

Cognitive Recovery icon
Cognitive Recovery
Remember and speak clearly.
Neurodegenerative Diseases icon
Neurodegenerative Diseases
Worldwide, 50 million people are living with Alzheimer's and other dementias.

Research Methods

Drug Discovery